XOMA (NASDAQ:XOMA) Earns Buy Rating from HC Wainwright

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $123.00 price target on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 349.23% from the company’s current price.

XOMA Trading Down 2.3 %

Shares of NASDAQ XOMA traded down $0.65 during midday trading on Friday, reaching $27.38. 8,970 shares of the stock were exchanged, compared to its average volume of 22,500. XOMA has a 12 month low of $15.56 and a 12 month high of $35.00. The company has a market capitalization of $322.54 million, a price-to-earnings ratio of -7.87 and a beta of 0.88. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The business has a 50-day simple moving average of $30.06 and a two-hundred day simple moving average of $27.66.

Insider Activity at XOMA

In related news, CEO Owen Hughes sold 21,881 shares of the stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total transaction of $655,335.95. Following the completion of the transaction, the chief executive officer now directly owns 34,979 shares in the company, valued at approximately $1,047,621.05. This trade represents a 38.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its position in shares of XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 795 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of XOMA by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock worth $4,840,000 after acquiring an additional 1,138 shares during the period. Rhumbline Advisers lifted its holdings in XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares during the last quarter. State Street Corp boosted its position in XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after purchasing an additional 1,754 shares during the period. Finally, Bank of New York Mellon Corp raised its position in shares of XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares during the period. Institutional investors own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.